OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI) in a reverse merger transaction on March 25, 2024. Pursuant to the BCA: (i) APx will merge with OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI and (ii) APx?s ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols ?OMNI? and ?OMNIW?, respectively. The transaction is subject to the approval of APx?s shareholders. The transaction is expected to close mid-year, 2024. The Business Combination Agreement may be terminated and the Transactions may be abandoned at any time prior to the Merger Effective Time, notwithstanding any requisite approval and adoption of the Business Combination Agreement and the Business Combination by the shareholders of the Company, At the Closing, OmnigenicsAI, Parent, the Company, the Sponsor, certain shareholders of the Company and Parent, the MultiplAI Shareholders and the OmnigenicsAI Heritas Key Personnel will enter into the Registration Rights and Lock-Up Agreement.

Antonio Peña, Arnaldo C. Rego, L. Frank Cordero, Stephen M. Pepper, Tyler J. Thompson, Manuel R. Valcarcel IV, and Henrietta Walker of Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen acted as U.S./U.K., Cayman and Argentine legal counsel, respectively, to APx. EarlyBirdCapital, Inc. acted as Financial advisor to APx. Matthew Poulter, Pierre-Emmanuel Perais, Gabriel Grossman, Andrew Gaines, Clara Pang, Michelle Lo, Sean McKeever, Antonia Sherman, Jamie Coomber, and Bruce Kilpatrick of Linklaters LLP, Ogier and Marval, O'Farrell & Mairal acted as U.S., Cayman and Argentine legal counsel, respectively, to OmnigenicsAI.